Using annexin V-coated magnetic beads to capture active tissue factor-bearing microparticles from body fluids

Cell Biology International

Volumn 38, Issue 2, 2014, Pages 277-281

  Gieseler, Frank ^a   Gamperl, Hans ^a   Theophil, Frederike ^a   Stenzel, Inga ^a   Quecke, Tabea ^a   Ungefroren, Hendrik ^a   Lehnert, Hendrik ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Annexin V; Cell derived microparticles; Magnetic beads

Indexed keywords

CALCIUM; LIPOCORTIN 5; MICROSPHERE; THROMBOPLASTIN;

BODY FLUID; FLOW CYTOMETRY; HUMAN; MAGNETISM; MEMBRANE MICROPARTICLE; METABOLISM; NEOPLASM; PATHOLOGY;

ANNEXIN A5; BODY FLUIDS; CALCIUM; CELL-DERIVED MICROPARTICLES; FLOW CYTOMETRY; HUMANS; MAGNETIC PHENOMENA; MICROSPHERES; NEOPLASMS; THROMBOPLASTIN;

EID: 84895901610     PISSN: 10656995     EISSN: 10958355     Source Type: Journal    
DOI: 10.1002/cbin.10216     Document Type: Article

References (31)

1. Ahamed J, Versteeg HH, Kerver M, Chen VM, Mueller BM, Hogg PJ, Ruf W (2006) Disulfide isomerization switches tissue factor from coagulation to cell signaling. Proc Natl Acad Sci USA 103: 13932-7.
2. Angelillo-Scherrer A (2012) Leukocyte-derived microparticles in vascular homeostasis. Circ Res 110: 356-69.
3. Aupeix K, Hugel B, Martin T, BischoffP, Lill H, Pasquali JL, Freyssinet JM (1997) The significance of shed membrane particles during programmed cell death in vitro, and in vivo, in HIV-1 infection. J Clin Invest 99: 1546-54.
4. Burger D, Schock S, Thompson CS, Montezano AC, Hakim AM, Touyz RM (2013) Microparticles: biomarkers and beyond. Clin Sci (Lond) 124: 423-41.
5. Burnier L, Fontana P, Kwak BR, Angelillo-Scherrer A (2009) Cellderived microparticles in haemostasis and vascular medicine. Thromb Haemost 101: 439-51.
6. Delabranche X, Berger A, Boisrame-Helms J, Meziani F (2012) Microparticles and infectious diseases. MedMal Infect 42: 335-43.
7. Eilertsen KE, Osterud B (2005) The role of blood cells and their microparticles in blood coagulation. Biochem Soc Trans 33: 418-22.
8. Furie B, Furie BC (2008) Mechanisms of thrombus formation. N Engl J Med 359: 938-49.
9. Gieseler F, Luhr I, Kunze T, Mundhenke C, Maass N, Erhart T, Denker M, Beckmann D, Tiemann M, Schulte C, Dohrmann P, Cavaille F, Godeau F, Gespach C (2007) Activated coagulation factors in human malignant effusions and their contribution to cancer cellmetastasis and therapy. ThrombHaemost 97: 1023-30.
10. Horstman LL, Jy W, Jimenez JJ, Ahn YS (2004) Endothelial microparticles as markers of endothelial dysfunction. Front Biosci 9: 1118-35.
11. Kasthuri RS, Taubman MB, Mackman N (2009) Role of tissue factor in cancer. J Clin Oncol 27: 4834-8.
12. Lacroix R (2010) The importance of pre-analytics in microparticle (MP) analysis. International Society on Thrombosis and Hemostasis, 56th Annual Scientific and Standardization Cammittee Meeting, Cairo, Egypt. 75-6.
13. Lacroix R, Robert S, Poncelet P, Dignat-George F (2010) Overcoming limitations of microparticle measurement by flow cytometry. Semin Thromb Hemost 36: 807-18.
14. McVey M, Tabuchi A, Kuebler WM (2012) Microparticles and acute lung injury. Am J Physiol Lung Cell Mol Physiol 303: L364-81.
15. Miltenyi-Biotec, Bergisch-Gladbach, Germany (2013) http://www.miltenyibiotec.com.
16. Morel O, Jesel L, Freyssinet JM, Toti F (2011) Cellular mechanisms underlying the formation of circulating microparticles. Arterioscler Thromb Vasc Biol 31: 15-26.
17. Moss SE, Edwards HC, Crumpton MJ (1991) Diversity in the annexin family. Springer: Novel Calcium-Binding Proteins; pp. 535-66.
18. Muralidharan-Chari V, Clancy JW, Plou C, Romano M, D'Souza-Schorey C (2009) ARF6-regulated shedding of tumor cellderived plasma membrane microvesicles. Curr Biol 10: 1875-85.
19. Owens AP, III Mackman N (2011) Microparticles in hemostasis and thrombosis. Circ Res 108: 1284-97.
20. Pendurthi UR, Ghosh S, Mandal SK, Rao LV (2007) Tissue factor activation: is disulfide bond switching a regulatory mechanism? Blood 110: 3900-8.
21. Piccin A, Murphy WG, Smith OP (2007) Circulating microparticles: pathophysiology and clinical implications. Blood Rev 21: 157-71.
22. Press JZ, Reyes M, Pitteri SJ, Pennil C, Garcia R, GoffBA, Hanash SM, Swisher EM (2012) Microparticles from ovarian carcinomas are shed into ascites and promote cell migration. Int J Gynecol Cancer 22: 546-52.
23. Reinhardt C, von Bruhl ML, Manukyan D, Grahl L, Lorenz M, Altmann B, Dlugai S, Hess S, Konrad I, Orschiedt L, Mackman N, Ruddock L, Massberg S, Engelmann B (2008) Protein disulfide isomerase acts as an injury response signal that enhances fibrin generation via tissue factor activation. J Clin Invest 118: 1110-22.
24. Schaffner F, Ruf W (2008) Tissue factor and protease-activated receptor signaling in cancer. Semin Thromb Hemost 34: 147-53.
25. Stagnara J, Garnache Ottou F, Angelot F, Mourey G, Seilles E, Biichle S, Saas P, Racadot E (2012) Correlation between plateletderived microparticle enumeration by flow cytometry and phospholipid-dependent procoagulant activity in microparticles: the centrifugation step matters! Thromb Haemost 107: 1185-7.
26. Tait JF, Gibson D (1992) Phospholipid binding of annexin V: effects of calcium and membrane phosphatidylserine content. Arch Biochem Biophys 298: 187-91.
27. Thomas GM, Panicot-Dubois L, Lacroix R, Dignat-George F, Lombardo D, Dubois C (2009) Cancer cell-derived microparticles bearing P-selectin glycoprotein ligand 1 accelerate thrombus formation in vivo. J Exp Med 206: 1913-27.
28. Versteeg HH, Schaffner F, Kerver M, Petersen HH, Ahamed J, Felding-Habermann B, Takada Y, Mueller BM, Ruf W (2008) Inhibition of tissue factor signaling suppresses tumor growth. Blood 111: 190-9.
29. Yuana Y, Osanto S, Bertina RM (2012) Use of immuno-magnetic beads for direct capture of nanosized microparticles from plasma. Blood Coagul Fibrinolysis 23: 244-50.
30. Zwaal RF, Schroit AJ (1997) Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 89: 1121-32.
31. Zwicker JI, Liebman HA, Neuberg D, Lacroix R, Bauer KA, Furie BC, Furie B (2009) Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res 15: 6830-40.